TNXP — Tonix Pharmaceuticals Holding C

Is TNXP overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Tonix Pharmaceuticals Holding C (TNXP) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $2.88. The rating moved from Strong Oversold to Oversold on October 28, 2026.

See all oversold Healthcare stocks →

AI analysis

Tonix Pharmaceuticals Holding C is a small, early‑stage biotech whose value is tied to clinical and partnership catalysts rather than current revenues. The company faces typical micro‑cap biotech risks: limited runway, potential dilutive financing, binary clinical/regulatory outcomes and low liquidity, while any positive readouts or strategic collaborations could materially boost valuation. Given sector flows favoring large‑cap pharma and the absence of broad social or EDGAR visibility, near‑term movement is likely to be event‑driven and volatile; investors should monitor cash runway disclosures, upcoming trial timelines, and any partnership announcements closely.

Key factors

  • Early‑stage biotech profile with limited or uncertain near‑term revenue; valuation primarily driven by pipeline and binary clinical/regulatory events
  • Pipeline and clinical catalysts potential — upcoming or expected trial readouts, partner deals or licensing could re-rate the stock if positive
  • Balance sheet and cash runway uncertainty for a small‑cap biotech; potential need for financing that could dilute existing shareholders
  • Sector dynamics favor large‑cap pharma and defensive healthcare, which limits sector flows into smaller, higher‑beta biotech names
  • Low liquidity and high share‑price volatility typical of micro‑cap biotechs; price sensitive to news flow and sentiment

Risks

  • Clinical trial failures or negative readouts leading to material share price declines
  • Need for additional financing (equity or convertible financing) causing dilution
  • Regulatory delays or unfavorable FDA interactions that push timelines and increase costs
  • Limited commercial infrastructure or partnering risk if a program advances toward approval
  • Competitive risk from larger pharma/biotech with deeper pockets and faster development timelines
  • Low visibility in filings and social/research coverage increases information asymmetry and execution risk

See today's live rating, score and targets

Members see the live hourly rating for TNXP — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.